

**ANNEX 1**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cimalgex 8 mg chewable tablets for dogs  
Cimalgex 30 mg chewable tablets for dogs  
Cimalgex 80 mg chewable tablets for dogs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

### Active substance:

Cimalgex 8 mg	cimicoxib 8 mg
Cimalgex 30 mg	cimicoxib 30 mg
Cimalgex 80 mg	cimicoxib 80 mg

For the full list of excipients see section 6.1.

## 3. PHARMACEUTICAL FORM

Chewable tablets.

Cimalgex 8 mg, tablets: oblong, white to pale brown, chewable tablets with 1 break-line on both sides. The tablets can be divided into equal halves.

Cimalgex 30 mg, tablets: oblong, white to pale brown, chewable tablets with 2 break-lines on both sides. The tablets can be divided into equal thirds.

Cimalgex 80 mg, tablets: oblong, white to pale brown, chewable tablets with 3 break-lines on both sides. The tablets can be divided into equal quarters.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Dogs

### 4.2 Indications for use, specifying the target species

For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs.

### 4.3 Contraindications

Do not use in dogs less than 10 weeks of age.

Do not use in dogs suffering from gastrointestinal disorders or haemorrhagic disorders.

Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs). Refer also to section 4.8

Do not use in case of hypersensitivity to cimicoxib or to any of the excipients.

Do not use in breeding, pregnant and lactating animals.

### 4.4 Special warnings for each target species

None.

### 4.5 Special precautions for use

Special precautions for use in animals

Since the safety of the medicinal product has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months. Use in animals suffering from impaired cardiac, renal or hepatic function, may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring.

Avoid using this product in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity.

Use this veterinary medicinal product under strict veterinary monitoring where there is a risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to NSAIDs.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Cimicoxib may cause skin sensitisation. Wash hands after use.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

People with a known hypersensitivity to cimicoxib should avoid contact with the veterinary medicinal product.

#### **4.6 Adverse reactions (frequency and seriousness)**

Mild and transient gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported.

On rare occasions, serious gastrointestinal disorders such as haemorrhage and ulcer formation have been noted. Other adverse reactions including anorexia or lethargy may also be observed on rare occasions.

In very rare cases, increases in renal biochemistry parameters were noted. Furthermore, in very rare cases, renal failure has been reported. As for any long term NSAID treatment, renal function should be monitored.

If any observed adverse effect persists after stopping treatment, the advice of a veterinarian should be sought.

If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy or worsening of renal or hepatic biochemistry parameters occur, use of the product should be discontinued and appropriate monitoring and/or treatment should be put in place.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Do not use in breeding, pregnant or lactating bitches. Although no data are available in dogs, studies with laboratory animals have shown effects on their fertility and foetal development.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

Cimalgex should not be administered in conjunction with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with Cimalgex. The treatment-free period should take into account the pharmacokinetic properties of the veterinary medicinal product used previously.

#### 4.9 Amounts to be administered and administration route

Oral use.

The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily.

The following table is presented as an example of how the tablets and tablet parts could be used in order to reach the recommended dose.

Bodyweight kg	8 mg	30 mg	80 mg
2	1/2		
3	1		
4	1		
5		1/3	
6	1+1/2		
7-8	2		
9-11	2+1/2		
12	3		
13-17		1	
18-22			1/2
23-28		1+2/3	
29-33		2	
34-38		2+1/3	
39-43			1
45-48		3	
49-54			1+1/4
55-68			1+1/2

The choice of the most suitable tablet type or tablet parts is left to the discretion of the veterinarian based on the circumstances in each case, without leading to important over- or underdosing.

#### Treatment duration:

- Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian.
- Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.

Cimalgex tablets can be administered with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.

#### 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

In an overdose study where 3 times (5.8 to 11.8 mg/kg body weight) and 5 times (9.7 to 19.5 mg/kg body weight) the recommended dose was administered to dogs for a period of 6 months, a dose related increase in gastrointestinal disturbances, which affected all dogs in the highest dose group, was noted.

Similar dose related changes to haematology and white blood cell counts, as well as renal integrity, were also noted.

As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs.

There is no specific antidote to this product. Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline.

#### **4.11 Withdrawal period**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

Pharmacotherapeutic group: non-steroidal anti-inflammatory drug, ATCvet code: QM01AH93

#### **5.1 Pharmacodynamic properties**

Cimicoxib is a non-steroidal anti-inflammatory drug belonging to the coxib group and acting by selective inhibition of the enzyme cyclo-oxygenase 2. The cyclo-oxygenase enzyme (COX) is present in two isoforms. COX-1 is usually a constitutive enzyme expressed in tissues, which synthesize products responsible for normal physiologic functions (e.g. in the gastro-intestinal tract and kidneys). COX-2 on the other hand, is mainly inducible and synthesized by macrophages and inflammatory cells after stimulation by cytokines and other mediators of inflammation. COX-2 is involved in the production of mediators, including PGE<sub>2</sub>, that induce pain, exudation, inflammation and fever.

In an *in vivo* inflammatory acute pain model, it was shown that the simulated effect of cimicoxib lasted for approximately 10-14 hours.

#### **5.2 Pharmacokinetic particulars**

After oral administration in dogs at the recommended dose of 2 mg/kg without food, cimicoxib is rapidly absorbed and the time to maximal concentration ( $T_{max}$ ) is 2.25 ( $\pm$  1.24) hours. The peak concentration ( $C_{max}$ ) is 0.3918 ( $\pm$  0.09021)  $\mu$ g/ml, area under the curve (AUC) is 1.676 ( $\pm$  0.4735)  $\mu$ g.hr/ml, and oral bioavailability is 44.53 ( $\pm$  10.26) percent.

The oral administration of cimicoxib with food did not significantly influence the bioavailability but decreased significantly the observed  $T_{max}$ .

Metabolism of cimicoxib is extensive. The major metabolite, demethylated cimicoxib is mainly eliminated in faeces by the biliary route and, to a lesser extent, in urine. The other metabolite, glucuronide conjugate of the demethylated cimicoxib, is eliminated in urine. The elimination half-life ( $t_{1/2}$ ) is 1.38 ( $\pm$  0.24) hours. The metabolising enzymes have not been fully investigated and slower metabolism (up to four-fold increased exposure) has been noted in some individuals.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Lactose monohydrate  
Povidone K25  
Crospovidone  
Sodium laurylsulfate  
Macrogol 400  
Sodium stearyl fumarate  
Pork liver powder

#### **6.2 Incompatibilities**

None known.

#### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years

Any remaining divided tablets should be discarded after 2 days storage in the blisters.  
Any remaining divided tablets should be discarded after 90 days storage in the bottle.

#### **6.4. Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

Any divided tablets should be stored in the blister pack/bottle.

#### **6.5 Nature and composition of immediate packaging**

All strengths are available in the following pack sizes and types:

- Aluminium blisters (each strip containing 8 tablets) packaged into an outer cardboard box. Pack sizes of 8, 32 or 144 tablets.
- Plastic (HDPE) bottle with child resistant plastic (PP) closure packaged into an outer cardboard box. Pack sizes of 45 tablets.

#### **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

### **7. MARKETING AUTHORISATION HOLDER**

Vétoquinol SA  
Magny Vernois  
70200 Lure  
France

### **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/10/119/001-012

### **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

18/02/2011

### **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency: <http://www.ema.europa.eu/>

### **PROHIBITION OF SALE, SUPPLY AND/OR USE**

Not applicable.

## **ANNEX II**

- A. MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE**
- C. STATEMENT OF MRLs**
- D. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE STATEMENT OF MRLs**

**A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE**

Vétoquinol SA  
Magny-Vernois  
70200 Lure  
France

**B. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE**

To be supplied only on veterinary prescription.

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

**C. STATEMENT OF THE MRLs**

Not applicable.

**D. CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT**

Not applicable.



**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Outer carton (for both blisters and bottle)**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cimalgex 8 mg chewable tablets for dogs  
Cimalgex 30 mg chewable tablets for dogs  
Cimalgex 80 mg chewable tablets for dogs

cimicoxib

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

8 mg cimicoxib  
30 mg cimicoxib  
80 mg cimicoxib

**3. PHARMACEUTICAL FORM**

Chewable tablets

**4. PACKAGE SIZE**

8 tablets  
32 tablets  
144 tablets  
45 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATIONS**

**7. METHOD AND ROUTES OF ADMINISTRATION**

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

**9. SPECIAL WARNINGS, IF NECESSARY**

**10. EXPIRY DATE**

EXP {MM/YYYY}

**11. SPECIAL STORAGE CONDITIONS**

**12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: Read Package Leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Vétoquinol SA  
Magny-Vernois  
70200 Lure  
France

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/10/119/001  
EU/2/10/119/002  
EU/2/10/119/003  
EU/2/10/119/004  
EU/2/10/119/005  
EU/2/10/119/006  
EU/2/10/119/007  
EU/2/10/119/008  
EU/2/10/119/009  
EU/2/10/119/010  
EU/2/10/119/011

EU/2/10/119/012

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Bottle pack**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cimalgex 8 mg tablets for dogs  
Cimalgex 30 mg tablets for dogs  
Cimalgex 80 mg tablets for dogs

cimicoxib

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

8 mg cimicoxib  
30 mg cimicoxib  
80 mg cimicoxib

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

45 tablets

**4. ROUTES OF ADMINISTRATION**

Oral use

**5. WITHDRAWAL PERIOD**

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cimalgex 8 mg chewable tablets for dogs  
Cimalgex 30 mg chewable tablets for dogs  
Cimalgex 80 mg chewable tablets for dogs  
cimicoxib



**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Vétoquinol

**3. EXPIRY DATE**

EXP {month/year}

**4. BATCH NUMBER**

Lot {number}

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**



**PACKAGE LEAFLET**  
**Cimalgex 8 mg chewable tablets for dogs**  
**Cimalgex 30 mg chewable tablets for dogs**  
**Cimalgex 80 mg chewable tablets for dogs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Vétoquinol SA  
Magny Vernois  
70200 Lure  
France

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Cimalgex 8 mg chewable tablets for dogs  
Cimalgex 30 mg chewable tablets for dogs  
Cimalgex 80 mg chewable tablets for dogs

Cimicoxib

**3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS**

Each tablet contains:

Cimicoxib 8 mg  
Cimicoxib 30 mg  
Cimicoxib 80 mg

Cimalgex 8 mg tablets are oblong, white to pale brown, with a break-line on both sides and can be divided into equal halves.

Cimalgex 30 mg, tablets: oblong, white to pale brown, chewable tablets with 2 break-lines on both sides. The tablets can be divided into equal thirds.

Cimalgex 80 mg, tablets: oblong, white to pale brown, chewable tablets with 3 break-lines on both sides. The tablets can be divided into equal quarters.

**4. INDICATIONS**

For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs.

**5. CONTRAINDICATIONS**

Do not use in dogs less than 10 weeks of age.

Do not use in dogs suffering from stomach or digestive system disorders or in dogs with bleeding problems.

Do not use at the same time as corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).

Do not use if the dog is hypersensitive to cimicoxib or any of the other ingredients in the product.

Do not use in breeding, pregnant or lactating animals (see Section 12 “Special precautions for dogs”).

## 6. ADVERSE REACTIONS

Mild gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported but these only lasted for a short time.

On rare occasions, serious gastrointestinal problems such as bleeding and ulcer formation have occurred. Other adverse reactions including loss of appetite or lethargy may also be observed on rare occasions.

In very rare cases, increases in kidney function results (renal biochemistry parameters) were noted. Furthermore, in very rare cases, renal failure has been reported. As for any long term NSAID treatment, kidney function should be monitored.

If any observed adverse effect persists after stopping treatment, the advice of your veterinary surgeon should be sought.

If adverse reactions such as persistent vomiting, repeated diarrhoea, blood in the stools, sudden weight loss, loss of appetite, lethargy or worsening of liver or kidney function results occur, use of the product should be discontinued and the advice of your veterinary surgeon should be sought immediately.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports).

## 7. TARGET SPECIES

Dogs.

## 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Oral use.

The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily.

The following table is presented as an example of how the tablets and tablet parts could be used in order to reach the recommended dose.

Bodyweight kg	8 mg	30 mg	80 mg
2	1/2		
3	1		
4	1		
5		1/3	
6	1+1/2		
7-8	2		
9-11	2+1/2		
12	3		
13-17		1	
18-22			1/2
23-28		1+2/3	
29-33		2	
34-38		2+1/3	

39-43			1
45-48		3	
49-54			1+1/4
55-68			1+1/2

The choice of the most suitable tablet type or tablet parts is left to the discretion of the veterinarian based on the circumstances in each case, without leading to important over- or underdosing.

Treatment duration:

- Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of your veterinary surgeon.
- Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by your veterinary surgeon.

Cimalgex tablets can be given to dogs with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.

**9. ADVICE ON CORRECT ADMINISTRATION**

None.

**10. WITHDRAWAL PERIOD**

Not applicable.

**11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Blister packs - Any remaining divided tablets should be stored in the blisters but discarded if not used within 2 days.

Bottles - Any remaining divided tablets should be stored in the bottle but discarded if not used within 90 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the label.

**12. SPECIAL WARNINGS**

Special precautions for use in animals

The safety of this veterinary medicinal product has not been established in young dogs, so careful monitoring by your veterinary surgeon is recommended if the dog is less than 6 months of age.

Use in animals suffering from impaired cardiac, renal or hepatic function, may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring. Avoid using this product in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity.

Use this veterinary medicinal product under strict veterinary monitoring in dogs with a risk of stomach ulcers or if the animal previously displayed intolerance to other NSAIDs.

### Special precautions for people

Cimicoxib may cause skin sensitisation. Wash hands after use of the veterinary medicinal product.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

People with a known hypersensitivity to cimicoxib should avoid contact with the veterinary medicinal product.

### Pregnancy and lactation

Do not use in breeding, pregnant or lactating bitches. Although no data are available in dogs, studies with laboratory animals have shown effects on their fertility and foetal development.

Cimalgex should not be administered in conjunction with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before starting treatment with Cimalgex. The treatment-free period should take into account the pharmacokinetic properties of the veterinary medicinal products used previously.

### Overdose (symptoms, emergency procedures, antidotes):

In an overdose study where 3 times (5.8 to 11.8 mg/kg body weight) and 5 times (9.7 to 19.5 mg/kg body weight) the recommended dose was administered to dogs for a period of 6 months, a dose related increase in gastrointestinal disturbances, which affected all dogs in the highest dose group, was noted.

Similar dose related changes to haematology and white blood cell counts, as well as renal integrity, were also noted.

As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs.

There is no specific antidote to this product. Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline.

## **13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Medicines should not be disposed of via wastewater or household waste.

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.

## **14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

Detailed information on this product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>

## **15. OTHER INFORMATION**

Cimicoxib is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID) drug. It selectively inhibits the cyclooxygenase 2 enzyme (COX-2), which is responsible for pain, inflammation or fever.

The cyclooxygenase 1 enzyme (COX-1) which has protective functions, for example, in the digestive tract and kidneys, is not inhibited by cimicoxib.

After oral administration in dogs at the recommended doses, cimicoxib is rapidly absorbed. Metabolism of cimicoxib is extensive. The major metabolite, demethylated cimicoxib is mainly eliminated in faeces by the biliary route and, to a lesser extent, in urine. The other metabolite, glucuronide conjugate of the demethylated cimicoxib, is eliminated in urine.

In an artificially induced pain model in dogs it was shown that the pain and inflammation reducing effects of cimicoxib lasted for approximately 10-14 hours.

All strengths of Cimalgex tablets are available in the following pack sizes and types:

- Aluminium blisters (each strip containing 8 tablets) packaged into an outer cardboard box. Pack sizes of 8, 32 or 144 tablets.
- Plastic (HDPE) bottle with child resistant plastic (PP) closure packaged into an outer cardboard box. Pack size of 45 tablets.

Not all pack sizes may be marketed.